Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06591091 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Study acronym: CLIMB
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Mar 2026 to Dec 2026 · Study sites: 0 to 1 · Start date changed from estimate of Sep 2025 to Dec 10, 2025v4 Show 3 more changesShow less
    • Primary and study completion dates: Mar 2026 to Dec 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2025 to Dec 10, 2025
  2. Start date: Apr 2025 to Sep 2025v3
  3. Primary completion date: Jan 2025 to Mar 2026 Start date: Oct 2024 to Apr 2025 · Primary endpoints revised (4) · Completion date: Mar 2025 to Mar 2026 · 3 morev2 Show 6 more changesShow less
    • Start date: Oct 2024 to Apr 2025
    • Primary endpoints revised (4)
    • Completion date: Mar 2025 to Mar 2026
    • Interventions: Clemastine Fumarate (Drug) to Clemastine Fumarate (Drug), Placebo (Drug)
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: details revised at 1 of 3 entries

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.
Trial Details
NCT Number NCT06591091
Lead Sponsor University of Illinois at Chicago
Collaborators: Cures Within Reach
Conditions Depression
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov